QIAGEN launches bloodstream infection testing panel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
QIAGEN Expands Into Bloodstream Infection Syndromic Testing With New Rapid QIAstat-Dx Panel
April 14, 2026 4:05 PM EDTQIAstat-Dx BCID GPF Plus AMR Panel detects gram-positive bacteria, fungi and key antimicrobial resistance markers from positive blood cultures and colonies CE-IVDR-certified panel identifies 20 pathogens and 10 resistance targets in about one hour to enable faster clinical decision-making Launch marks QIAGENs expansion into bloodstream infection syndromic testing, building on earlier panels for respiratory, gastrointestinal and meningitis / encephalitis testing
HILDEN, Germany & VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its expansion into syndromic testing for... More
